Understanding the Causes and Potential Treatments for Heart Defects in Noonan Syndrome
Recent Yale research uncovers the molecular mechanisms behind heart defects in Noonan syndrome and highlights a promising drug that could offer new treatment options for affected children.
Noonan syndrome with multiple lentigines (NSML) is an uncommon genetic disorder characterized by features such as short stature, distinctive facial appearances, and dark skin spots called lentigines. However, the most dangerous aspect of NSML is its propensity to cause hypertrophic cardiomyopathy—a severe thickening of the heart muscle—whose underlying mechanisms have remained unclear.
Recent research from Yale School of Medicine has advanced our understanding of how specific genetic mutations lead to this heart complication and has identified a promising therapeutic option. The study, published in the Proceedings of the National Academy of Sciences, reveals that mutations in the gene coding for the enzyme SHP2 play a pivotal role. Unlike prior assumptions that reduced enzymatic activity drove the disease, Yale scientists discovered that the problem lies in SHP2 acting as a scaffold, recruiting other proteins such as c-Src to initiate abnormal signaling cascades.
This abnormal signaling elevates key transcription factors that interfere with normal heart development, leading to a decline in BMP10, a protein essential for healthy heart muscle formation. Interestingly, the research highlighted that a leukemia drug called dasatinib, which inhibits c-Src activity, can restore BMP10 levels and prevent heart muscle thickening in animal models at very low doses.
The implications are significant: repurposing existing drugs like dasatinib could pave the way for effective treatments for children with NSML, who often face life-threatening heart failure early in life due to hypertrophic cardiomyopathy. This discovery offers new hope for targeted therapy that addresses the genetic and molecular roots of the condition.
Dr. Sravan Perla, the lead researcher, emphasized the importance of this breakthrough, stating that the path from gene to heart function has been clearly mapped, increasing confidence that such strategies can benefit patients in clinical settings. Future clinical trials will be essential to determine the safety and effectiveness of this approach in humans, potentially leading to a life-saving treatment for those affected by Noonan syndrome-related heart defects.
Source: https://medicalxpress.com/news/2025-09-uncovering-drivers-treatment-noonan-syndrome.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Can Adults Be Trained to Better Recognize and Avoid Sick Faces?
Research shows that adults can enhance their ability to identify sick faces through targeted training, aiding early disease detection and prevention.
Innovative Exercise MRI Technique Enhances Heart Disease Diagnosis
A new exercise-based MRI technique allows clinicians to observe real-time heart responses during physical activity, facilitating earlier and more accurate diagnosis of heart disease.
First Detection of West Nile Virus in the UK: What It Means for Public Health
The UK has for the first time detected West Nile virus in mosquitoes, raising awareness about potential future risks as climate change may facilitate its spread. Learn about the virus, transmission, and current risks in the UK.
New Insights into the Enzymatic Mechanisms Behind Rare Metabolic Disorder
A groundbreaking study uncovers how a specific mutation in the enzyme cystathionine beta-synthase disrupts its function in rare metabolic disorder, opening new avenues for tailored treatments.